anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic pain is a complex, debilitating, and escalating health problem worldwide, impacting 1 in 5 adults. Current treatment is compromised by dose-limiting side effects, including high abuse liability, loss of ability to function socially and professionally, fatigue, drowsiness, and apathy. PICK1 has emerged as a promising target for the treatment of chronic pain conditions. Here, we developed and characterized a cell-permeable fatty acid-conjugated bivalent peptide inhibitor of PICK1 and assessed its effects on acute and chronic pain. The myristoylated PICK1 inhibitor, myr-NPEG4-(HWLKV)2 (mPD5), self-assembled into core-shell micelles that provided favorable pharmacodynamic properties and relieved evoked mechanical and thermal hypersensitivity as well as ongoing hypersensitivity and anxiodepressive symptoms in mouse models of neuropathic and inflammatory pain following subcutaneous administration. No overt side effects were associated with mPD5 administration, and it had no effect on acute nociception. Finally, neuropathic pain was relieved far into the chronic phase (18 weeks after spared nerve injury surgery) and while the effect of a single injection ceased after a few hours, repeated administration provided pain relief lasting up to 20 hours after the last injection.
Elevations of blood hepatic enzyme values [alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT)] are commonly seen in patients with immediately life- threatening VT/VF. Interpreting elevated AST activity can be difficult because the values may be elevated in patients who have had recent myocardial infarction, congestive heart failure, or multiple electrical defibrillations. Approximately 54% of patients receiving intravenous amiodarone in clinical studies had baseline liver enzyme elevations, and 13% had clinically significant elevations. In 81% of patients with both baseline and on-therapy data available, the liver enzyme elevations either improved during therapy or remained at baseline levels. Baseline abnormalities in hepatic enzymes are not a contraindication to treatment. Elevated bilirubin levels have been reported in patients administered intravenous amiodarone. 

Acute, centrolobular confluent hepatocellular necrosis leading to hepatic coma, acute renal failure, and death has been associated with the administration of intravenous amiodarone ( see Dosage and Administration ( 2) ). 

In patients with life-threatening arrhythmias, the potential risk of hepatic injury should be weighed against the potential benefit of amiodarone therapy. Carefully monitor patients receiving amiodarone for evidence of progressive hepatic injury. In such cases, consider reducing the rate of administration or withdrawing amiodarone.
Temperature regulation and decision-making are vital aspects of human survival where relatively small deviations in whole-body heat balance lead to decrements in physical performance and cognitive function. Prolonged exposure to cold stress combined with inadequate clothing and/or insufficient heat production can lead to decreases in body temperature causing mild hypothermia (≤ -1.0˚C in body temperature). Performance in the cold is more physically demanding compared to neutral environments (\~22˚C) as there is increased cardiovascular strain due to a strong peripheral vasoconstriction reducing cerebral and muscle blood flow and oxygenation, reduced neuromuscular capacity, as well as changes in energy metabolism during shivering and increased catecholamine release. Additionally, there is an increased psychological strain where perceptually there is a high thermal discomfort, alterations in neurotransmitters (e.g. dopamine, norepinephrine), and alterations in mood. These changes lead to decreases in self-paced cycling time-trial performance in the cold with mild hypothermia compared to thermoneutral environments. Additionally, there appears to be task-dependent cognitive changes with acute cold stress, where higher-order functions such as executive function, working memory, and inhibitory control decrease before simple task performance such as reaction time and visual recognition/awareness. Currently, it is unknown what the potential mechanisms are that lead to these performance decrements.

The decrements in both self-paced exercise and cognitive function may be due to alterations in neurotransmitters caused by hypothermia. Exposure to cold leads to alterations in dopamine, and norepinephrine which may affect prefrontal cortex function, which may explain why higher-order executive function tasks such as inhibitory control and spatial planning are impaired compared to simple task performance. Previously, it has been determined that the use of tyrosine (amino acid precursor to dopamine and norepinephrine neurotransmitters) supplementation improves working memory and executive function despite a -2.0˚C drop in body temperature through cold-water immersion, but not in thermoneutral conditions. However, it is unknown what the role of dopamine or central nervous system stimulants are in the cold. Methylphenidate is a central nervous system stimulant through dopamine re-uptake inhibition is demonstrated to improve executive function task performance in healthy adults in thermoneutral conditions. Additionally, methylphenidate has been demonstrated to improve self-paced cycling performance by 16% in the heat (30˚C) but not thermoneutral environments (1). Methylphenidate is also demonstrated to improve maximal force production during fatiguing exercise, indicating it may play a role in reducing the effects of fatigue during endurance exercise. The investigators aim to determine the role of the central nervous system using methylphenidate on cognitive function and self-paced exercise in the cold.
A redifferentiated dermal fibroblast cell that exhibits at least one characteristic of a chondrocyte. A proteoglycan is used to induce re-differentiation of the cell. In some embodiments, the cell expresses of at least one cartilage proteoglycan marker. The proteoglycan may comprise aggrecan and the cell may differentiate from the fibroblast along the chondrogenic lineage.  
     A method of inducing chondrogenesis in a fibroblast cell comprises culturing the fibroblast cell on a surface containing at least one cartilage-derived proteoglycan other than perlecan. A three-dimensional scaffold may be coated with the proteoglycan and seeded with fibroblast cells. The fibroblast cells may be contacted with at least one chondrogenic growth factor or cytokine prior to said culturing.
Patients received Everolimus 4 weeks after kidney transplant until the end of the study, administered orally twice a day. The dose was adjusted in order to maintain a trough level between 3-8 ng/mL. Patients received mycophenolic acid until everolimus was initiated.
PURPOSE:To obtain the titled powder containing innumerable fine pores and having excellent dyeability with natural dye and high fastness of the dyed product to water, by suspending fine particles of water-insoluble carbonate in an aqueous solution of silk fibroin, adding a coagulating salt to the suspension, stirring the mixture, treating with an acid, washing with water, and pulverizing the product after drying. CONSTITUTION:Fine particles of a water-insoluble carbonate (preferably soft calcium carbonate having an average particle diameter of <=0.1mu) or the carbonate particles and an extender pigment (preferably talc, etc.) are suspended in an aqueous solution of silk fibroin (preferably produced by dissolving refined raw silk in an aqueous solution of hydrochloride or nitrate of Ca, Mg or Zn, and subjecting the solution to dialysis and desalting). The suspension is added with a coagulating salt (preferably sodium chloride, etc.), agitated at a high shear rate, treated with an acid (preferably hydrochloric acid, etc.), washed with water, dried and pulverized to obtain the objective powder composed of regenerated silk fibroin fine powder (containing extender pigment) (preferably having a crystallinity of 20-43% and maximum particle diameter of 3-30mu) containing pores having a pore diameter of <=1mu in an amount of <=300mul/g, preferably >=600mul/g, and containing >=50wt%, preferably >=90wt% fibroin insoluble in hot water. USE:Cosmetics, foods, paint, etc.
Patients receive paclitaxel as in arm I and pazopanib hydrochloride PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After including the patients into the study, patient needs to sign a written consent. After that, the next appointment will be scheduled. On the next appointment, each patient included in this study will undergo ultrasound cleaning and receive guidance for adequate everyday oral hygiene. The next appointment, after 10 days will be scaling and root planing for selected periodontal pockets. Because it is painful treatment, anesthesia is needed to be administrated. Patients will be split into three groups by picking cards, for receiving different doses of 4% articaine with 1:100,000 epinephrine ORABLOC® (40 mg/ml Articaine + 0.01 mg/ml Epinephrine, PIERREL S.P.A, Capua, Italy) in each group. Doses will be 0.1 ml, 0.2 ml, and 0.3 ml of 4% articaine with epinephrine for one appointment scaling and root planing. Anesthesia will be obtained by CCLADS device Anaject® (Septodont, Sallanches, Franc). The Intraseptal anesthesia (ISA) will be the method of administrating the anesthesia. Parameters of the device will be a mode with constant pressure, injection speed - mode LOW 0.005 ml/s. Time for application will depend on the dose, and it will be 20 s for 0.1 ml, 40 s for 0.2 ml, and 60 s for 0.3 ml.

Parameters of local anesthesia will be recorded by the pin-prick test. The pain will be rated by the visual-analogue scale (VAS). The pain will be rated immediately upon termination of the local anesthetic delivery and during the scaling and root planing.

Patients will be followed up the next day for local side effects and their need for analgesic medication.
Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
Recently studies reported that gut microbiota is related to the human immunity modulation of allergic diseases. Investigators are interested to know weather qi-tonifying herbal medicine is through the changes of gut microbiota to modulate human immunity. In this study, a double-blinded, randomized, placebo control design is applied and total 60 perennial allergic rhinitis patients will be enrolled in our study. All subjects will be divided into Bu-Zhong-Yi-Qi-Tang (BZYQT) and placebo control groups, 40 and 20 subjects each. Subjects of BZYQT group will receive capsule of BZYQT, 4gm tid, 12gm a day, while control group will receive similar placebo capsule with same scheme. Total 2 months treatment course will be done. Gut microbiota will be assayed before and after 2 months treatment. Additionally, various parameters for immunologic response will be checked before and after the treatment, including the total IgE amount, the ratio of CD4/CD8 of T lymphocytes, the profile of cytokine such as IL-10 and IL-12 as well as functional change of dendritic cells and T cells. Results will be analyzed statistically including gender analysis. This study will provide the evidences of gut microbiota changes and immune-modulatory effects of BZYQT for the treatment of allergic rhinitis.
Drug: Piperacillin Sodium and Tazobactam Sodium for Injection. Dosing regimen: GA\<28 weeks: 30 mg/kg, Q8H; 28 weeks ≤GA\<34 weeks: 50 mg/kg，Q8H.
In adult placebo-controlled clinical trials across the approved adult populations from baseline to endpoint, duloxetine treatment was associated with mean increases of 0.5 mm Hg in systolic blood pressure and 0.8 mm Hg in diastolic blood pressure compared to mean decreases of 0.6 mm Hg systolic and 0.3 mm Hg diastolic in placebo-treated patients. There was no significant difference in the frequency of sustained (3 consecutive visits) elevated blood pressure.

Patients receiving DRIZALMA SPRINKLE should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies [see Adverse Reactions (6.1)]. Pre-existing hypertension should be controlled before initiating treatment with DRIZALMA SPRINKLE. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure.

Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving DRIZALMA SPRINKLE, either dose reduction or discontinuation should be considered [see Adverse Reactions (6.1), Drug Interactions (7.1)]].
PURPOSE: To compare the clinical efficacy and complication rates between the medial midline and anterolateral portals in ankle arthroscopy for treating medial osteochondral lesions of the talus (OLTs).
METHODS: We retrospectively analyzed patients with medial OLTs who underwent either a dual medial approach (via the medial midline and anteromedial portal) or a traditional approach (via the anterolateral and anteromedial portal) between June 2017 and January 2023. The degree of injury was evaluated by radiographs, computed tomography, and magnetic resonance imaging. Clinical outcomes were assessed using the visual analog scale (VAS), the American Orthopaedic Foot and Ankle Society (AOFAS) score, and the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scoring system. The incidence of postoperative complications, including superficial peroneal nerve (SPN) injury, was evaluated in all patients.
RESULTS: There were 39 patients in total; 16 patients underwent the dual medial approach, and 23 patients underwent the traditional approach. The mean age was 39.4 ± 9.0 years, and the mean follow-up duration was 18.7 ± 6.4 months. The clinical outcomes improved significantly in both groups (*P < 0.05), but there was no significant difference between the two groups (P > 0.05). Postoperative complications were mainly SPN injury. The incidence of SPN injury was 13.0% in the traditional approach group and 0% in the dual medial approach group, with no significant difference between the two groups (P > 0.05), but a trend of reduction in SPN injury was observed in the dual medial approach group.
CONCLUSION: The dual medial approach can also treat medial OLTs well, providing clear visualization and more convenient operation and reducing the possibility of injury to the SPN compared with the traditional approach. Therefore, we consider that the MM portal would be a good alternative to the anterolateral portal in treating medial OLTs.
Due to supply difficulties and other factors associated with COVID-19, oral dexamethasone became less readily available. To address this limitation, we investigated the effect of adjusting prophylactic antiemetic therapy on the efficacy of anticancer drug treatment. This study included patients in the gastrointestinal oncology unit of our hospital who received a regimen containing moderately emetogenic risk anticancer drugs between September 2021 and August 2022. We retrospectively analyzed medical records to assess the treatment regimen, prophylactic antiemetic therapy, oral dexamethasone dose reduction, presence of emetic events during the first course, use of additional antiemetic agents for prominent nausea and vomiting, and the complete response(CR)rate. The study included 98 patients with a median age of 71 years. The overall CR rate was 95% in the standard-dose dexamethasone group and 92.3% in the dexamethasone-reduced group(p=0.68). The CR rates for oxaliplatin- and irinotecan-based regimens were 92.9% and 100% in the dexamethasone-reduced group and 91.5% and 94.7% in the standard-dose dexamethasone group. In this study, the CR rates were not significantly different between the dexamethasone reduction and standard-dose groups. This may be due to the use of steroid-sparing or triple therapy by physicians, depending on the patient's risk factors. Therefore, the prophylactic antiemetic therapies for individual patients must be continued to examine.
Sweet taste receptors, similar to those located on the lingual taste buds have been located along in the lining of the gut. Recent studies have demonstrated that activation of these sweetness taste receptors, either by sugars such as glucose, fructose, lactose, or artificial sweeteners such as saccharin and aspartame can influence the way nutrients, including glucose are absorbed from the gut into the bloodstream. Studies in animal models have shown that activation of the sweet taste receptors can increase the expression of the sodium-dependant glucose transporter 1 (SGLT1) and glucose transporter 2 (GLUT2) which transport glucose from the lumen into the bloodstream. Thus providing a potential mechanism by which glucose uptake can be regulated. Although artificial sweeteners stimulate the sweet taste receptors, they have little nutritive value, so that when they are consumed in the absence of any other nutrients there is little effect on blood glucose response. However, the effects of consuming artificial sweeteners in combination with sugars such as glucose is unclear. The purpose of this study is to investigate whether the addition of artificial sweeteners to an orally consumed glucose solution affects the rate at which the glucose appears in the blood.
This is a two-part clinical trial. The first part will be a dose escalation phase involving preoperative radiation therapy to determine the maximum tolerated dose (MTD). The second part will be a dose expansion in which an additional 6 patients will be studied at the MTD for further experience with safety and efficacy. The dose escalation portion of the trial will have six cohorts or arms. Cohort 1 will receive the standard dose of 30 Gy in 5 fractions. Subsequent cohorts will have patients receiving 30 GY in 5 fractions to the planning target volume with dose-escalation of the gross tumor volume (GTV) to 35Gy, 40 Gy, 45 Gy and 50 Gy. An interim analysis will be performed after 40 Gy to assess toxicity.
BACKGROUND: Obesity is closely associated with upper gastrointestinal disorders. The recommendations for routine preoperative esophagogastroduodenoscopy (EGD) before bariatric surgery remains a topic of debate. This study aimed to describe the pathological endoscopic findings in individuals qualified for bariatric surgery.
METHODS: Retrospective analysis was conducted on preoperative gastroscopy reports of patients who underwent bariatric surgery at our hospital between October 2022 and October 2023.
RESULTS: A total of 405 patients were included in the study. The two most prevalent endoscopic findings during EGD in this patient cohort were chronic superficial gastritis (326/405, 80.5%) and reflux esophagitis (82/405, 20.2%). Some patients exhibited two or more abnormalities. Patients with reflux esophagitis were older, had a higher proportion of men, higher BMI, higher rates of smoking and drinking compared to those without it (P = 0.033, P < 0.001, P = 0.003, P = 0.001, and P = 0.003, respectively). Morbid obesity (P = 0.037), smoking habits (P = 0.012), and H. pylori infection (P = 0.023) were significant risk factors for reflux esophagitis in male patients, while age (P = 0.007) was the sole risk factor in female patients. No statistically significant differences were observed in surgical procedures between LA-A and B groups (P = 0.382), but statistically significant differences were noted between the nondiabetic and diabetic groups (P < 0.001).
CONCLUSIONS: Preoperative EGD can unveil a broad spectrum of pathologies in patients with obesity, suggesting the need for routine examination before bariatric surgery. The findings of this study can guide bariatric surgeons in developing tailored treatments and procedures, thus significantly enhancing prognosis. Gastroscopy should be performed routinely in Chinese patients planning to undergo bariatric surgery.
The auricular therapy group received an intervention based on the bilateral application of 7 adhesive tapes with vaccaria seeds. The points were located with a retractable 250 gr. pressure palpator (Sedatelec®). An experienced health professional trained on acupuncture techniques applied the vaccaria seeds.
To minimize the risk of bleeding following the vascular instrumentation during the treatment of unstable angina, non–Q-wave myocardial infarction and acute ST-segment elevation myocardial infarction, adhere precisely to the intervals recommended between enoxaparin sodium doses. It is important to achieve hemostasis at the puncture site after PCI. In case a closure device is used, the sheath can be removed immediately. If a manual compression method is used, sheath should be removed 6 hours after the last intravenous/subcutaneous enoxaparin sodium injection. If the treatment with enoxaparin sodium is to be continued, the next scheduled dose should be given no sooner than 6 to 8 hours after sheath removal. The site of the procedure should be observed for signs of bleeding or hematoma formation [see Dosage and Administration (2.1)].
The invention relates to the field of medicinal preparations. In order to increase the solubility of nimodipine in water, nimodipine injection sold on the market at home and abroad contains a great amount of organic solvent, but the high total content of organic solvent causes overlarge stimulation to blood vessels during direct injection, and a series of adverse effects such as phlebitis and the like are easily caused. The invention aims to provide a nimodipine injection composition, and a preparation method and application thereof. The preparation method comprises the following steps of: dissolving the nimodipine in a small amount of organic solvent for injection to obtain injection; and mixing with a small volume of emulsion to obtain the nimodipine injection composition. When the nimodipine injection composition is used, the injection in the composition is mixed with the small volume of emulsion, and intravenous injection is performed, or the composition mixed solution is dispersed in 5 percent glucose or physiological saline for intravenous drip. The injection composition has the advantages of high loading rate, low consumption of auxiliary materials, low toxicity, high stability, convenience in administration and the like; and during clinical administration, a three-way valve is not needed for assistance, a medicine is prevented from being separated out in the infusion process, and the administration safety is effectively improved.
Objectives: This study characterized toothache-related Portuguese Facebook posts, identifying factors driving misinformation production and user engagement. Methods: Investigators qualitatively analyzed 500 posts published between August 2018 and August 2022, screening on language and theme. Posts were selected using CrowdTangle and assessed for motivation, author profile, content, sentiment, facticity, and format. The interaction metrics (total interactions/overperforming scores) were compared between groups of dichotomized characteristics, including time of publication. Data were evaluated by descriptive analysis, the Mann-Whitney U test, and the path analysis by generalized structural equation modeling. Results: 39.6% of posts (n = 198) contained misinformation, significantly linked to noncommercial posts with positive sentiment, links, and videos from regular users motivated by financial motivation. Additionally, user engagement was only positively associated with business/health authors' profiles and the time of publication. Conclusion: Toothache-related posts often contain misinformation, shared by regular users in links and video formats, tied to positive sentiments, and generally with financial motivation.